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Abstract
The unambiguous identification of oligodendrocytes in tissue
sections, especially in myelinated tracts, is often difficult. Most of
the antibodies used to identify oligodendrocytes label the myelin
sheath as well. Originally described as an inhibitor of axonal
outgrowth, Nogo-A is known to be strongly expressed in mature
oligodendrocytes in vivo. In the present investigation we analyzed
the expression patterns of Nogo-A in adult mouse and human CNS
as well as in demyelinating animal models and multiple sclerosis
lesions. Nogo-A expression was compared with that of other
frequently used oligodendroglial markers such as CC1, CNP, and
in situ hybridization for proteolipid protein mRNA. Nogo-A
strongly and reliably labeled oligodendrocytes in the adult CNS
as well as in demyelinating lesions and thus represents a valuable
tool for the identification of oligodendrocytes in human and mouse
CNS tissue.
Key Words: Cuprizone-induced demyelination, Experimental
autoimmune-mediated encephalomyelitis, Multiple sclerosis,
Nogo-A, Oligodendrocytes.
INTRODUCTION
The unambiguous identification of oligodendrocytes
in tissue sections, especially in myelinated tracts, is often a
challenge. Most oligodendrocyte markers used for labeling
of oligodendrocytes in human and mouse formalin-fixed
and paraffin-embedded tissues recognize oligodendrocytes
as well as myelin. The present Bgold standard[ for the
identification of oligodendrocytes is proteolipid protein
(PLP) or myelin basic protein (MBP) mRNA in situ
hybridization (1, 2), a time-consuming and expensive
technique (3). Antibodies such as MBP, myelin oligoden-
drocyte glycoprotein (MOG) and myelin-associated glyco-
protein (MAG) reliably label myelin sheaths, but less
frequently the cytoplasm of oligodendrocytes. CNP is a
reliable marker of oligodendrocytes in demyelinated lesions
(4, 5); however, in myelinated tracts the CNP-positive
oligodendrocytes often cannot be distinguished from
intensely stained myelinated fibers. The identification of
additional immunohistochemical markers that selectively
stain the oligodendrocytic cytoplasm but not the myelin
sheath is desirable. Therefore, we performed a detailed
immunohistochemical study to analyze whether Nogo-A,
which is expressed strongly in the oligodendrocyte cell body
but only weakly in neurons and some myelin fibers, might be
such a marker.
Nogo-A and its splice variants Nogo-B and -C belong
to the reticulon family. They have a common carboxy
terminus of 188 amino acids and share 172 amino acids at
the N terminus. Nogo-A is expressed in oligodendrocytes, in
the inner and outer loops of myelin sheaths, and in some
neuronal populations such as dorsal root ganglion cells,
retinal ganglion cells, and ventral horn neurons in spinal
cord (6Y8). Nogo-A was originally identified because of its
ability to prevent axonal regrowth and sprouting (9Y11).
Treatment with antibodies recognizing the N-terminal
epitope of Nogo-A (IN-1) resulted in improved regenerative
fiber outgrowth in rats with spinal cord trauma (9, 12).
Nogo-66, the extracellular domain shared by all Nogo splice
variants, signals via its receptor, the Nogo receptor, which is
localized on axons, some neurons, and astrocytes (13, 14).
Nogo-66 binds to the Nogo receptor and its coreceptor
p75NTR, thus controlling the effects of external stimuli on
growth cones (15). However, Nogo-A knockout mice do not
show any distinctive morphologic CNS defects or obvious
neurologic symptoms, indicating that Nogo-A is not essen-
tial for development and maintenance of axons, neurons, or
oligodendrocytes during development and in the adult CNS
(16Y18).
During recent years, it became apparent that Nogo-A
and its splice variants might have other functions in addition
to controlling axonal regrowth after injury. Nogo-B, for
example, is highly expressed in vascular smooth muscle and
endothelial cells, where it seems to prevent smooth muscle
cell migration (19, 20). Nogo-B was also found in cancer
cell lines (21, 22) as well as in interactions with antiapop-
totic proteins such as bcl-2 and bcl-xL (23). However, other
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studies could not demonstrate a change in spontaneous or
staurosporine-triggered apoptosis in tumor cell lines over-
expressing Nogo-B (22).
In this study, we compare the expression patterns of
Nogo-A in adult mouse and human CNS with other
frequently used oligodendroglial makers such as PLP mRNA
and CC1 (24). We show that Nogo-A reliably labels mature
oligodendrocytes in mouse paraffin-embedded CNS tissues.
No cross-reaction with other glial cells such as microglial
cells, astrocytes, or NG-2-positive cells was observed.
Furthermore, Nogo-A also reliably identifies oligodendro-
cytes in 2 demyelinating animal models, the toxic cuprizone
model and experimental autoimmune-mediated encephalo-
myelitis (EAE). In human myelinated and demyelinated
CNS tissues, immunohistochemistry for Nogo-A results in a
reliable identification of oligodendrocytes.
MATERIALS AND METHODS
Animal Models
Experimental Autoimmune Encephalomyelitis
All animal procedures were carried out in accordance
with the guidelines set forth by the Canadian Council for
Animal Care as approved by the McGill University animal
care committee. Female C57BL/6 mice (6Y8 weeks old,
n = 4) (The Jackson Laboratories, Bar Harbor, ME) were
immunized on each side at the base of the tail with a
subcutaneous injection of 100 Kg of MOG peptide 35Y55
(Sheldon Biotechnology Centre, Montreal, QC, Canada)
emulsified in complete Freund’s adjuvant (Fisher, Montreal,
QC, Canada) containing 500 Kg of heat-killed Mycobacte-
rium tuberculosis (H37RA; Difco, Detroit, MI). Mice
received intraperitoneal injections of 300 ng of pertussis
toxin (Sigma, Oakville, ON, Canada) in Hanks_ buffered
saline solution (Invitrogen, Burlington, ON, Canada) on the
day of the immunization and also 2 days later. Mice were
assessed daily for symptoms and weighed. The grading
scheme was as follows: Score 1 (partial floppy tail), Score 2
(floppy tail), Score 3 (floppy tail and slow to right), Score 4
(partial hindlimb paralysis), Score 5 (complete hindlimb
paralysis), and Score 6 (moribund or dead).
Cuprizone-Induced Demyelination
Male C57BL6/129 mice (7Y8 weeks old) were fed
with 0.3% cuprizone (Sigma, Seelze, Germany) mixed into
powdered food for up to 42 days. Mice were killed at Day 21
(n = 8) or Day 42 (n = 9) after onset of a cuprizone diet, as
were untreated control mice (n = 6) of the same age.
Human Tissue
Four-micrometer-thick paraffin-embedded tissue sec-
tions from temporal or occipital lobes of 6 patients who
underwent temporal or occipital lobe surgery because of
pharmacoresistant seizures (Table 1) as well as 1 multiple
sclerosis (MS) lesion were analyzed for the expression of
Nogo-A, MBP, MAG, CNP, and/or PLP mRNA.
Immunohistochemistry
Immunohistochemical staining of human and mouse
tissue was performed with an avidin-biotin technique. Brain,
spinal cord, spleen, and liver from 4 EAE mice and 5
nonimmunized control mice and the brains of cuprizone-
treated mice were embedded in paraffin. Cervical, thoracic,
and higher lumbar spinal cord was cut in 8 to 11 3-mm-thick
transverse segments before embedding. Frozen sections of
either perfusion-fixed (4% paraformaldehyde [PFA]) or
fresh-frozen (no perfusion with 4% PFA) CNS tissue
sections from control mice were post-treated with 0.1%
PFA, acetone, ethanol, ethanol and acetic acid, or methanol,
or given no post-treatment.
Paraffin-embedded tissue sections were deparaffinized,
and intrinsic peroxidase activity was blocked by incubation
with 5% H2O2 in PBS for 20 minutes. Nonspecific antibody
binding was inhibited with 10% fetal calf serum in PBS for
25 minutes. The primary antibodies were mouse anti-CC1
(Calbiochem, Darmstadt, Germany), rabbit anti-Nogo A
(Chemicon, Hampshire, UK), mouse anti-Nogo-A (11C7) (a
generous gift from M. E. Schwab (Brain Research Institute,
University of Zurich and Department of Biology, Swiss
Federal Institute of Technology, Zurich, Switzerland), anti-
2_,3_-cyclic nucleotide 3_-phosphodiesterase (anti-CNPase)
(Sternberger Monoclonals, Lutherville, MD), anti-myelin
basic protein (anti-MBP) (Dako, Glostrup, Denmark), anti-
MAG (a generous gift from C. Richter-Landsberg, University
of Oldenburg, Oldenburg, Germany), anti-MOG (8-18C5), (a
generous gift from C. Linnington, University of Aberdeen,
Aberdeen, UK), anti-NG2 (Chemicon), anti-MAC-3 (similar
or identical to CD107b (25) (PharMingen, San Diego, CA),
and anti-glial fibrillary acidic protein (GFAP) (Dako). For
dilution of antibodies and pretreatments, see Table 2.
In Situ Hybridization
Nonradioactive in situ hybridization (ISH) for PLP
mRNA was performed as described in detail previously (1)
TABLE 1. Age, Sex, and Clinical Information for Temporal Lobe Surgery Patients
Patient Age (years) Sex Clinical Findings Neuropathologic Findings
1 30 M Epilepsy since the age 3 Reactive gliosis in white matter and cortex
2 39 F Chronic epilepsy No pathologic changes
3 28 F Epilepsy with occipital focus No pathologic changes
4 43 F Pharmacoresistant epilepsy No pathologic changes
5 64 M Pharmacoresistant epilepsy Focal Ammon_s horn sclerosis
6 41 M Pharmacoresistant epilepsy Venous angioma
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with an automated immunostainer (Discovery; Ventana
Medical Systems, Tucson, AZ). Hybridization was per-
formed using digoxigenin-labeled riboprobes (Roche,
Mannheim, Germany) detected by alkaline phosphatase-
conjugated anti-digoxigenin Fab fragments (Roche). NBT/
BCIP (Roche, Mannheim, Germany) was used as a chrom-
ogen. For double staining after ISH, sections were incubated
with anti-PLP antibody (Biozol, Eching, Germany) and
processed as described above.
Morphometric Analysis
To determine the numbers of CC1-, Nogo-A-, and
PLP mRNA-positive cells in the corpus callosum of
healthy mice (n = 5) and mice treated with 0.3%
cuprizone, the number of labeled cells was counted in 10
high-power fields located in the middle of the corpus
callosum on coronal sections at the level of the anterior
commissure. To quantify the numbers of labeled cells in
the spinal cord of healthy control mice, 1 transversal spinal
cord segment of each spinal cord level (cervical, thoracic,
and lumbar level) was selected in each mouse, and the
number of labeled cells was determined in the dorsal
funiculus. Consecutive sections were stained and the same
transversal spinal cord segments were analyzed for the
different immunohistochemical stainings.
To quantify the demyelinated area in EAE mice, all
transverse spinal cord cross-sections were analyzed in each
animal (n = 4). The demyelinated area was measured in
sections stained for Luxol fast blue (LFB)/periodic acid-
Schiff (PAS) and expressed as percentage of total white
matter. For statistical analysis, the mean per animal was
calculated. The number of perivascular infiltrates was
counted in all transverse spinal cord cross-sections, and
the mean per animal was determined. To quantify the
numbers of CC1-, Nogo-A (monoclonal)-, and PLP
mRNA-positive cells in EAE lesions, the numbers of
labeled cells within the lesion areas of 2 or 3 transverse
spinal cord segments per mouse were counted. In all mice,
the same transverse spinal cord segments were analyzed.
Consecutive sections were stained with antibodies directed
against Nogo-A and CC1 and also were used for ISH with
a PLP mRNA probe.
Statistical Analysis
Statistical analysis was performed by using Prism
Software (GraphPad) or the Instat statistics program. To
analyze the numbers of Nogo-A-, CC1-, and PLP mRNA-
positive cells, an unpaired Student t-test was used.
RESULTS
Expression of Nogo-A in Adult Mouse Central
Nervous System
To analyze the specificity and sensitivity of the
oligodendrocyte marker Nogo-A, we compared the expres-
sion pattern of Nogo-A (Fig. 1AYF) with the expression
patterns of CC1 and PLP mRNA (Fig. 1G, H). We
investigated 2 different Nogo-A antibodies, the commer-
cially available polyclonal antibody (Chemicon) and the
monoclonal antibody 11C7 (26), hereafter termed Nogo-A
(pc) and Nogo-A (mc).
Both Nogo-A antibodies intensely stained the somata
of oligodendrocytes in the white matter tracts of brain
(Fig. 1E, F), cerebellum (Fig. 1B), and spinal cord (Fig. 1D),
as well as oligodendrocytes in the cortex (Fig. 1A), basal
ganglia, and grey matter of the spinal cord (Fig. 1C). Some
oligodendrocytes possessed short Nogo-A-positive pro-
cesses. Few myelin sheaths were labeled by both Nogo-A
antibodies. A subpopulation of neurons, including some
neurons in the cortex (Fig. 1A), hippocampus, spinal cord
(Fig. 1C), brainstem, or cerebellum (Purkinje cells)
(Fig. 1B), were labeled weakly by these 2 markers. The
TABLE 2. Source, Dilution, and Pretreatment of Antibodies
Antibody Source Pretreatment Dilution
mc mouse anti-CC1 Calbiochem Microwave, 10 mmol/L Tris/1 mmol/L EDTA,
pH 9, 5  3 min
1:20
mc mouse anti-CNP Sternberger Monoclonals Microwave, 10 mmol/L citrate buffer,
pH 6, 5  3 min
1:200
pc rabbit anti-GFAP Dako No pretreatment 1:1000
mc rat-anti-MAC-3 PharMingen Microwave, 10 mmol/L citrate buffer,
pH 6, 5  3 min
1:2000
pc rabbit anti-MAG Gift from C. Richter-Landsberg No pretreatment 1:1000
pc rabbit anti-MBP Dako No pretreatment 1:2000
mc mouse anti-MOG (8-18C5) Hybridoma (gift from C. Linnington) Microwave, 10 mmol/L citrate buffer,
pH 6, 5  3 min
1:20
mc mouse anti-Nogo-A (11C7) Gift from M. E. Schwab Microwave, 10 mmol/L citrate buffer,
ph 6, 5  3 min
1:15,000
(1:20,000)
pc rabbit anti-Nogo-A Chemicon Microwave, 10 mmol/L citrate buffer,
pH 6, 5  3 min
1:750
pc rabbit anti-NG2 Chemicon Microwave, 10 mmol/L Tris/1 mmol/L EDTA,
pH 9, 5  3 min
1:200
mc mouse anti-PLP Biozol Microwave, 10 mmol/L citrate buffer, pH 6, 5  3 min 1:500
mc, monoclonal; pc, polyclonal.
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strongest neuronal Nogo-A staining was observed in hypo-
glossal nuclei. The Nogo-A staining intensity of oligoden-
drocytes was clearly stronger than the Nogo-A signal of
most neurons. Staining of frozen tissue sections (either
derived from perfusion-fixed or fresh-frozen CNS speci-
mens) revealed a similar staining pattern. Post-treatment
with PFA, acetone, or ethanol or no post-treatment resulted
in intense labeling of oligodendrocytes. In addition, post-
treatment with acetone or 0.1% PFA or no post-treatment
revealed stronger labeling of some neuronal subgroups,
such as >-motoneurons (no post-treatment, 0.1% PFA, or
acetone) or Purkinje cells (acetone) compared with paraffin-
embedded tissue sections. Double immunohistochemistry of
Nogo-A with GFAP or NG2 revealed no double labeling of
Nogo-A with astrocytes or NG2-positive cells (Fig. 2A). In
contrast, all CC1-positive cells were also Nogo-A-positive
(Fig. 2CYE). To determine the sensitivity of these different
oligodendrocytic markers compared with that of other
frequently used oligodendroglial markers such as CC1 or
PLP mRNA, the number of oligodendrocytes labeled by
these different markers was counted in the corpus callosum
as well as in cervical, thoracic, and lumbar dorsal funiculus.
Within the corpus callosum, the numbers of labeled
oligodendrocytes did not differ significantly among these
different oligodendroglial markers (Fig. 3A). In contrast, in
the dorsal funiculus some differences were observed among
the different markers (Table 3). In all spinal cord regions
FIGURE 1. Expression pattern of Nogo-A in different CNS regions of the mouse and comparison with other oligodendroglial
markers. (A) In the cortex, oligodendrocytes showed a strong immunohistochemical signal for Nogo-A (monoclonal [mc])
(arrows). Only a few neurons were weakly labeled (arrowhead). (B) In cerebellum, anti-Nogo-A (mc) identified numerous
oligodendrocytes, and Purkinje cells were weakly labeled (arrowheads). (C) In the grey matter of the spinal cord,
oligodendrocytes were strongly stained with anti-Nogo-A (mc), but only few >-motoneurons showed a positive reaction. In
the dorsal funiculus (D) and the corpus callosum (E), numerous oligodendrocytes were identified by anti-Nogo-A (mc). Similar
numbers of oligodendrocytes were detected by immunohistochemistry with anti-Nogo-A (polyclonal) (F), anti-CC1 (G), or
proteolipid protein (PLP) mRNA in situ hybridization (H).
FIGURE 2. Nogo-A does not colocalize with NG2 but with
CC1. By double immunohistochemistry with anti-Nogo-A
(monoclonal [mc]) (red, arrows) and anti-NG2 (green, arrow-
heads) no colocalization of Nogo-A and NG2 was observed
either in normal CNS (A) or in the corpus callosum of mice
treated for 42 days with cuprizone (B). In contrast, all CC1-
positive cells (red) were also Nogo-A (mc)-positive (green)
(C–E).
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analyzed, PLP ISH detected more oligodendrocytes than
immunohistochemistry with antibodies directed against
Nogo-A or CC1. For most regions this difference was
significant (Fig. 3B; Table 3).
Expression of Nogo-A in Demyelinating Murine
Animal Models
To further analyze the specificity and sensitivity of
Nogo-A in the diseased CNS, we compared PLP mRNA
expression patterns with Nogo-A and CC1 immunohisto-
chemistry in MOG-EAE and cuprizone-induced demyelina-
tion, 2 demyelinating animal models affecting spinal cord or
brain, respectively. Because we did not observe any
significant differences in the staining patterns between the
mono- and polyclonal Nogo-A antibodies, we used the
monoclonal Nogo-A antibody 11C7 for the subsequent
experiments. PLP mRNA ISH and immunohistochemical
stainings were performed on consecutive sections.
Experimental Autoimmune-Mediated
Encephalomyelitis
The first clinical symptoms were observed at Day 14
(n = 2) or Day 16 (n = 2) after immunization with MOG.
One mouse had to be killed at Day 19 because of severe
clinical symptoms; the other mice had maximal disease
scores and were killed at Day 30 after immunization with a
disease score of 5 (n = 2) or 1 (n = 1). All 4 mice were
analyzed histologically. The extent of demyelination was
determined by measuring the area of white matter with loss
in LFB-PAS staining. Between 7.2% and 22.5% of the white
matter in the different animals showed a lack of LFB
FIGURE 3. Quantification of oligodendrocytes in different CNS regions and in different demyelinating models by different
oligodendroglial markers. In the corpus callosum, similar numbers of oligodendrocytes were identified by proteolipid protein
(PLP) mRNA in situ hybridization (ISH) or immunohistochemistry with antibodies directed against CC1 or Nogo-A (A). In the
thoracic dorsal funiculus significantly more oligodendrocytes were recognized by PLP mRNA ISH than by CC1 or Nogo-A
immunohistochemistry (PLP mRNA ISH: 1,293 T 62; CC1: 842 T 102, p = 0.006; Nogo-A (polyclonal): 640 T 53, p G 0.0001;
Nogo-A (11C7): 813 T 77, p = 0.0013) (B). Similar numbers of oligodendrocytes were labeled by the different oligodendroglial
markers in EAE lesions (PLP mRNA: 206 T 64 cells/mm2, CC1: 244 T 23 cells/mm2, Nogo-A (monoclonal): 293 T 40 cells/mm2
(C) and at different time points during the cuprizone diet (D).
TABLE 3. Numbers of PLP mRNA-, CC1-, Nogo-A (pc)- and
Nogo-A (mc)-Positive Cells in the Dorsal Funiculus of Different
Spinal Cord Levels
PLP mRNA CC1 Nogo-A (pc) Nogo-A (mc)
Cervical 1,007 T 98 745 T 62† 733 T 68† 740 T 65†
Thoracic 1,293 T 62 842 T 102** 640 T 53*** 813 T 77**
Lumbar 1,245 T 71 950 T 65* 656 T 44** 907 T 81*
All values are compared with numbers of PLP mRNA-positive cells.
PLP, proteolipid protein; pc, polyclonal; mc, monoclonal.
*, p G 0.05; **, p G 0.001; ***, p G 0.0001; †, not significant.
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staining (mean T standard error of the mean: 13.8 T 3.3%).
The distribution of the Nogo-A staining in brain was similar
to that in nonimmunized animals (see above). In the spinal
cord, in addition to oligodendrocytes some >-motoneurons
were strongly labeled by Nogo-A. Within the lesions, similar
numbers of oligodendrocytes were recognized by all oligo-
dendrocytic markers (PLP mRNA: 206 T 64 cells/mm2;
CC1: 244 T 23 cells/mm2; and Nogo-A (mc): 293 T 40 cells/
mm2), the differences between the different oligodendrocytic
markers were not significant (Fig. 3C). To exclude the
possibility that Nogo-A also stained astrocytes or macro-
phages/microglia in autoimmune-induced demyelination, we
performed double immunohistochemistry, which demonstra-
ted no colocalization of Nogo-A with macrophages/micro-
glia or astrocytes (Fig. 4A, B).
Cuprizone Model
Feeding of 0.3% cuprizone led selectively to the death
of mature oligodendrocytes in the brain, especially in the
corpus callosum. The loss of oligodendrocytes was accom-
panied by increased numbers of macrophage/microglial cells
and astrocytic gliosis. At Day 42 the medial parts of the
corpus callosum were almost completely demyelinated in
the majority of mice analyzed. The maximal loss of
oligodendrocytes was reached approximately 21 days after
onset of a cuprizone diet; after that, we observed that the
number of mature oligodendrocytes again increased
(Fig. 3D), a finding that has also been reported by others
(27). Similar numbers of oligodendrocytes were labeled by
the different oligodendrocyte markers at Day 0 (PLP mRNA:
975 T 59 cells/mm2; Nogo-A (mc): 1,257 T 75 cells/mm2;
and CC1: 1,277 T 84 cells/mm2), Day 21 (PLP mRNA: 76 T
25 cells/mm2; Nogo-A (mc): 90 T 26 cells/mm2; and CC1:
62 T 21 cells/mm2), and Day 42 (PLP mRNA: 656 T 138;
Nogo-A (mc): 529 T 84 cells/mm2; and CC1: 600 T 87 cells/
mm2) (Fig. 3D). As in EAE lesions, no colocalization of
Nogo-A with astrocytes or macrophages/microglial cells
(Fig. 4C, D) or NG2-positive cells (Fig. 2B) was found.
Expression of Nogo-A in Human Central
Nervous System
To investigate whether Nogo-A immunohistochemistry
sufficiently identifies oligodendrocytes in human paraffin-
embedded tissues, we stained white matter and cortex tissue
specimens from temporal or occipital lobes of 6 patients
who had undergone epilepsy surgery as well as specimens
from the lesion of 1 patient with MS. Different myelin
markers such as CNP, MAG, MBP, and PLP mRNA were
used to compare the results with Nogo-A immunohisto-
chemistry (Fig. 5).
The selected epilepsy cases showed no pathology
except for some reactive astrocytes and activated microglia
(Table 1). Nogo-A immunohistochemistry detected numer-
ous oligodendrocytes within the white matter (Fig. 5A). No
demyelination was seen with CNP, MBP, and MAG staining
(Fig. 5BYD). Identification of single oligodendrocytes was
not possible in any of these stainings. In 3 of 6 epilepsy
cases, strongly labeled oligodendrocytes were found by ISH
with a PLP mRNA probe (Fig. 5E). The other 3 cases
showed patchy staining patterns as well as tissue areas that
were completely negative. The MS lesion was characterized
by loss of myelin, perivascular and diffuse T cell infiltration,
numerous macrophages, and reactive astrocytes. Some
lesion areas showed thin, irregularly formed myelin sheaths
indicating remyelination. The monoclonal Nogo-A antibody
identified numerous oligodendrocytes within the lesions as
well as in the periplaque white matter as shown in Figure 5F.
In contrast, only few CNP or PLP mRNA-positive oligoden-
drocytes were detected within the lesion (Fig. 5G, J), and no
MBP- or MAG-positive oligodendrocytes were found
(Fig. 5H, I).
DISCUSSION
The present study demonstrates that Nogo-A is a
reliable marker of oligodendrocytes in paraffin-embedded
tissues of mouse and human CNS. Nogo-A is expressed in
oligodendrocytes in the white matter tracts of brain,
cerebellum, and spinal cord as well as in oligodendrocytes
within the cortex, basal ganglia, and grey matter of spinal
cord. Furthermore, Nogo-A reliably labels oligodendrocytes
in different demyelinating animal models and in human
demyelinating diseases such as multiple sclerosis. Because
of its strong staining of the oligodendroglial cytoplasm but
only weak staining of myelin sheaths, Nogo-A represents a
valuable tool for the identification of human and mouse
oligodendrocytes in paraffin-embedded tissues.
FIGURE 4. Nogo-A does not colocalize with glial fibrillary
acidic protein (GFAP) or MAC3 in demyelinating lesions in
animal models. In experimental autoimmune-mediated ence-
phalomyelitis (EAE) lesions, no colocalization of GFAP (green,
arrows) and Nogo-A (monoclonal [mc]) (red, arrowheads)
was observed (A). Double immunohistochemistry with anti-
bodies directed against the macrophage/microglial marker
MAC3 (green, arrows) and Nogo-A (mc) (red, arrowheads)
revealed that different cell populations were labeled by these
2 markers (B). Similar staining patterns were observed in the
corpus callosum in mice receiving a cuprizone diet for 42
days. No colocalization was observed with Nogo-A (mc) (red,
arrowheads) and the astrocytic marker GFAP (green, arrows)
(C) or the macrophage marker MAC3 (green, arrows) (D).
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Nogo-A expression has been described in the CNS
and, at lower levels, in testis and heart in adult rats (7).
Within the CNS of adult rats Nogo-A was reported to be
strongly expressed in the cytoplasm of oligodendrocytes, a
subpopulation of neurons, and the myelin in fresh-frozen
tissue sections (7). In paraffin-embedded tissue sections, we
observed the strongest Nogo-A expression within the
cytoplasm of oligodendrocytes and only weak or no labeling
in the majority of neurons. By using fresh-frozen or
perfusion-fixed frozen CNS tissue sections post-treated with
either 0.1% PFA and acetone or receiving no post-treatment,
we detected also a stronger Nogo-A signal in some
subpopulations of neurons similar to the results described
by Huber et al (7). However, neither in paraffin-embedded
sections nor in frozen sections did we find intense labeling of
the myelin sheaths. Instead, we saw a strong labeling of
some oligodendroglial processes, especially in remyelinating
MS lesions as well as a light and diffuse staining of the
myelinated tracts. This difference might be explained by the
different antibodies used in these 2 studies. Although we
observed similar numbers of Nogo-A, CC1, and PLP
mRNA-positive oligodendrocytes in the corpus callosum of
nondiseased mice, significantly fewer Nogo-A or CC1-
positive oligodendrocytes were found in the dorsal funiculus
in spinal cord. This difference is most likely not due to
methodologic problems. The stainings were performed on
consecutive sections, and care was taken to always analyze
the same tissue areas. In addition, this difference in the
numbers of CC1, Nogo-A, and PLP mRNA-positive cells
was obvious in different regions in the cervical, thoracic, and
lumbar spinal cord. These results indicate that PLP mRNA
ISH is more sensitive for the detection of oligodendrocytes
in spinal cord than immunohistochemistry for Nogo-A
or CC1.
Only limited data are available on the expression of
Nogo-A in demyelinating animal models such as EAE or
cuprizone-induced demyelination. Immunization with Nogo-
66, the extracellular domain shared by Nogo-A, -B and -C,
induced neurologic symptoms and histologic characteristics
similar to those seen in EAE (28). Mice vaccinated with
Nogo-A (623Y640) or treated with a neutralizing antibody
against Nogo and immunized with MOG peptide showed
improved clinical symptoms, reduced numbers of inflamma-
tory infiltrates, and less tissue damage (29). In the present
study we have shown that Nogo-A is expressed in a pattern
in mice immunized with MOG peptide similar to that in
nonimmunized animals. Oligodendrocytes in apparently
unaffected white matter as well as in inflammatory lesions
showed a strong Nogo-A signal. Neurons in the brain of
EAE mice presented with the same staining patterns as that
in nonimmunized mice. In addition, some >-motoneurons in
the spinal cord of EAE mice displayed more intense Nogo-A
FIGURE 5. Nogo-A reliably labels Nogo-A-positive oligoden-
drocytes in human CNS tissues and multiple sclerosis (MS)
lesions. (A–E) Images were taken from the same temporal
lobe biopsy of a patient who underwent epilepsy surgery. (A)
Numerous oligodendrocytes were easily identified by immu-
nohistochemistry with anti-Nogo-A antibody (mc). (B–D) The
myelinated fibers showed no sign of demyelination as
demonstrated by immunohistochemistry for 2,3-cyclic
nucleotide 3-phosphodiesterase (CNPase), myelin basic pro-
tein (MBP), and myelin-associated glycoprotein (MAG). Note
that oligodendrocytes were not labeled more intensely than
myelin sheaths (immunohistochemistry for CNPase, MBP, and
MAG, brown). (E) Proteolipid protein (PLP) mRNA in situ
hybridization (ISH) identified some of the oligodendrocytes,
but the staining signal was diffuse (PLP mRNA ISH [black]
combined with PLP immunohistochemistry [red]). (F–J)
Images were taken from the same MS lesion. (F) Numerous
oligodendrocytes in the lesion and the periplaque white
matter were labeled by anti-Nogo-A (monoclonal) (brown).
(G) Only single CNPase-positive oligodendrocytes were
identified (brown, arrows). (H, I) Immunohistochemistry with
antibodies against MBP and MAG led to an intensive staining
of the periplaque white matter, but no oligodendrocytes
could be identified. (J) ISH with a PLP mRNA probe detected
only single oligodendrocytes (black, arrows).
Kuhlmann et al J Neuropathol Exp Neurol  Volume 66, Number 3, March 2007
 2007 American Association of Neuropathologists, Inc.244
 by guest on January 9, 2017
http://jnen.oxfordjournals.org/
D
ow
nloaded from
 
Copyright @ 2007 by the American Association of Neuropathologists, Inc. Unauthorized reproduction of this article is prohibited.
staining compared with nonimmunized animals. The signifi-
cance of this observation is not clear, but it may be spec-
ulated that the upregulation of Nogo-A in >-motoneurons
is a reaction to inflammatory changes and axonal damage
in EAE lesions. In EAE lesions, similar numbers of cells
were labeled by the different oligodendroglial markers.
However, slightly fewer oligodendrocytes were identified
by PLP mRNA ISH compared with Nogo-A (mc)-positive
cells. This finding is in contrast to the higher numbers of
PLP mRNA-positive cells observed in the spinal cord of
untreated control mice. These results may indicate that
mRNA levels of myelin proteins react more sensitively
to autoimmune-induced demyelination than the proteins, as
has been observed in early stages of cuprizone-induced
demyelination (30).
Feeding of cuprizone for 4 to 5 weeks leads to
oligodendroglial cell death and extensive demyelination in
the corpus callosum, with the lowest numbers of mature
oligodendrocytes at about Day 28 (27). By 6 weeks,
approximately 50% of axons are remyelinated despite
ongoing cuprizone diet. This remyelination is accompanied
by increasing numbers of oligodendroglial precursors as well
as mature oligodendrocytes (27). We identified similar
numbers of oligodendrocytes with the 3 oligodendroglial
markers at all time points. As expected and in line with the
earlier studies mentioned above (27, 30), the lowest numbers
of oligodendrocytes were observed at Day 21. Similar
numbers of Nogo-A, CC1, and PLP mRNA-positive oligo-
dendrocytes were found at Day 42, suggesting that there is
no major temporal difference in the re-expression of these
myelin genes during remyelination. This finding is in
agreement with earlier studies demonstrating similar time
courses for different myelin genes during remyelination in
the cuprizone model (30, 31). Together, these results
demonstrate that Nogo-A is a specific and reliable oligoden-
droglial marker in the de- and remyelinating phase of the
cuprizone model.
In human paraffin-embedded tissues, the identification
of oligodendrocytes, especially in myelinated tracts, is
challenging. The most frequently used immunohistochem-
ical markers, such as CNP or MOG, also stain the myelin
sheath, often making unambiguous identification of oligo-
dendrocytes difficult. Markers that reliably label the oligo-
dendrocytic cytoplasm but not the myelin in mouse tissues,
such as CC1, do not cross-react with human antigens. ISH
for PLP or MBP mRNA is an expensive and time-consuming
procedure and requires RNase-free handling of samples that
is not feasible in routine neuropathology work. To analyze
whether Nogo-A represents a suitable oligodendroglial
marker for human biopsy tissues, we compared the staining
patterns of different myelin/oligodendrocyte markers such as
MBP, MAG, CNP, and PLP mRNA ISH with Nogo-A
immunohistochemistry in CNS tissues from patients who
underwent epilepsy surgery and in 1 MS lesion. As
described in previous studies, immunohistochemistry with
Nogo-A resulted in intense labeling of the oligodendroglial
cytoplasm and some oligodendroglial processes, whereas the
myelin showed only a weak staining signal (6). These results
are partly in contrast to those of Satoh et al (32), who
reported a strong Nogo-A signal of oligodendrocytes in MS
lesions, but a weak labeling of only a subpopulation of
oligodendrocytes in normal appearing white matter. In our
study, immunohistochemistry for Nogo-A identified the
majority of oligodendrocytes in normal appearing as well
as demyelinated CNS tissue. Furthermore, Nogo-A immu-
nohistochemistry proved to be more robust and reliable than
PLP mRNA ISH or any other immunohistochemical marker
in the identification of oligodendrocytes in human biopsies.
In conclusion, Nogo-A is a valuable tool for identify-
ing oligodendrocytes in adult human and mouse CNS as well
as in demyelinated lesions.
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